色素沈着症治療市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、治療・治療法別、エンドユーザー別、地域別、競合別、2020-2030年

世界の色素沈着症治療市場は、2024年に67億8,000万米ドルと評価され、予測期間中にCAGR 7.13％で成長し、2030年には102億5,000万米ドルに達すると予測されています。

色素沈着障害は、色素沈着過剰と色素沈着低下を包含し、日焼け、遺伝、炎症、ホルモン変化などの要因により皮膚の色調に影響を与えます。これらの疾患は美容上の懸念が顕著になるため、多くの人々がより透明で均一な肌のために治療を求めるようになります。美意識が高まり、美容が重視されるにつれ、外用剤、ケミカルピーリング、レーザー治療、ダーマブレージョンなどの治療に対する需要は増加の一途をたどっています。人口の高齢化、皮膚科学における技術革新、先進的な製剤や機器の導入が、市場の拡大をさらに後押ししています。さらに、スキンケアに焦点を当てた消費者教育や製品開拓、特にハイドロキノンやナイアシンアミドなどの有効成分を含むクリームの急増が、市場の成長軌道に大きく寄与しています。

市場促進要因

技術の進歩

主な市場課題

治療コスト

主な市場動向

個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の色素沈着症治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（色素沈着過度、色素脱失）
  • 治療と療法別（ケミカルピーリング、皮膚剥離、レーザーリサーフェシング、肝斑）
  • エンドユーザー（皮膚科クリニック、病院）別
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の色素沈着症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の色素沈着症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の色素沈着症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の色素沈着症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの色素沈着症治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の色素沈着症治療市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Zerigo Health.
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Bayer AG
• CLINUVEL PHARMACEUTICALS LTD
• Strides Pharma Science Limited
• Astellas Pharma Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Pigmentation Disorders Treatment Market was valued at USD 6.78 Billion in 2024 and is projected to reach USD 10.25 Billion by 2030, growing at a CAGR of 7.13% during the forecast period. Pigmentation disorders, encompassing hyperpigmentation and hypopigmentation, affect skin coloration due to factors such as sun exposure, genetics, inflammation, and hormonal changes. These conditions can result in noticeable cosmetic concerns, leading many individuals to seek treatment for clearer, more even-toned skin. With rising awareness and the increasing emphasis on aesthetics, demand for treatments like topical agents, chemical peels, laser therapies, and dermabrasion continues to grow. Aging populations, technological innovation in dermatology, and the introduction of advanced formulations and devices have further propelled market expansion. Additionally, a surge in skincare-focused consumer education and product development-particularly creams containing active ingredients such as hydroquinone and niacinamide-has significantly contributed to the market's growth trajectory.

Key Market Drivers

Technological Advancements

Rapid advancements in technology have greatly enhanced the effectiveness and precision of pigmentation disorder treatments. Innovations in laser-based therapies, including Q-switched, fractional, and picosecond lasers, have enabled targeted treatment of pigmented lesions with minimal risk of scarring. The adoption of Intense Pulsed Light (IPL) systems has broadened treatment accessibility for conditions such as age spots and sun-induced pigmentation. In addition, fractional radiofrequency (RF) devices that integrate microneedling with RF energy offer effective non-invasive treatment with minimal downtime. The refinement of topical formulations through nanotechnology and enhanced transdermal delivery systems has increased the potency and bioavailability of active ingredients. Cryotherapy tools with improved temperature control, along with the emergence of picosecond lasers capable of ultra-short pulse durations, have expanded therapeutic options, especially for resistant pigmentation conditions. These technological strides have collectively improved clinical outcomes and patient satisfaction across diverse skin types and indications.

Key Market Challenges

Cost of Treatment

The high cost of pigmentation treatment poses a significant challenge for broader market accessibility. Procedures such as laser therapy and combination treatment plans can be expensive, especially when multiple sessions are required for optimal results. Out-of-pocket expenses can be substantial, particularly in regions where pigmentation therapy is classified as elective and not covered by insurance. Beyond procedural fees, patients also bear the costs of consultation, follow-ups, prescription creams, and maintenance therapies. Premium skincare products designed for pigmentation disorders can be financially burdensome, and specialized treatments often involve travel to advanced dermatology centers, further escalating costs. The long-term nature of treatment, requiring consistent care and follow-up, adds to the financial strain, thereby limiting treatment adoption among cost-sensitive populations.

Key Market Trends

Personalized Medicine

The shift toward personalized medicine is transforming the treatment of pigmentation disorders. Tailored therapeutic strategies are now being developed based on individual patient factors such as genetic profile, skin type, lifestyle, and prior treatment responses. Genetic insights have enabled identification of mutations and variations linked to pigmentation irregularities, helping clinicians develop targeted therapies. Pharmacogenomic testing further refines this approach by determining the most effective drug or topical agent based on an individual's genetic makeup. Skin type-specific therapies and the integration of multimodal treatments-such as combining chemical peels with laser resurfacing-are gaining traction. Moreover, advancements in laser technology now permit customization of wavelength and energy settings based on patient-specific needs. Empowering patients with information and involving them in treatment decisions is also a key feature of this trend, contributing to improved adherence and satisfaction.

Key Market Players

• Zerigo Health
• Bausch Health Companies Inc.
• Glenmark Pharmaceuticals Limited
• Novartis AG
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd
• Bayer AG
• CLINUVEL PHARMACEUTICALS LTD
• Strides Pharma Science Limited
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Pigmentation Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pigmentation Disorders Treatment Market, By Indication:

• Hyperpigmentation
• Hypopigmentation

Pigmentation Disorders Treatment Market, By Treatment & Therapies:

• Chemical Peels
• Dermabrasion
• Laser Resurfacing
• Melasma

Pigmentation Disorders Treatment Market, By End User:

• Dermatology Clinics
• Hospitals

Pigmentation Disorders Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pigmentation Disorders Treatment Market.

Available Customizations:

Global Pigmentation Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pigmentation Disorders Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Hyperpigmentation, Hypopigmentation)
  • 5.2.2. By Treatment & Therapies (Chemical Peels, Dermabrasion, Laser Resurfacing, Melasma)
  • 5.2.3. By End User (Dermatology Clinics, Hospitals),
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Pigmentation Disorders Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Treatment & Therapies
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Pigmentation Disorders Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Treatment & Therapies
      • 6.3.1.2.3. By End User
  • 6.3.2. India Pigmentation Disorders Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Treatment & Therapies
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Pigmentation Disorders Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Treatment & Therapies
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Pigmentation Disorders Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Treatment & Therapies
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Pigmentation Disorders Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Treatment & Therapies
      • 6.3.5.2.3. By End User

7. Europe Pigmentation Disorders Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Treatment & Therapies
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pigmentation Disorders Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Treatment & Therapies
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Pigmentation Disorders Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Treatment & Therapies
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Pigmentation Disorders Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Treatment & Therapies
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pigmentation Disorders Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Treatment & Therapies
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Pigmentation Disorders Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Treatment & Therapies
      • 7.3.5.2.3. By End User

8. North America Pigmentation Disorders Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Treatment & Therapies
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Pigmentation Disorders Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Treatment & Therapies
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Pigmentation Disorders Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Treatment & Therapies
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Pigmentation Disorders Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Treatment & Therapies
      • 8.3.3.2.3. By End User

9. South America Pigmentation Disorders Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Treatment & Therapies
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pigmentation Disorders Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Treatment & Therapies
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Pigmentation Disorders Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Treatment & Therapies
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Pigmentation Disorders Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Treatment & Therapies
      • 9.3.3.2.3. By End User

10. Middle East and Africa Pigmentation Disorders Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Treatment & Therapies
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pigmentation Disorders Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Treatment & Therapies
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Pigmentation Disorders Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Treatment & Therapies
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Pigmentation Disorders Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Treatment & Therapies
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pigmentation Disorders Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Zerigo Health.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Bausch Health Companies Inc.
• 16.3. Glenmark Pharmaceuticals Limited
• 16.4. Novartis AG
• 16.5. Pfizer Inc.
• 16.6. Teva Pharmaceutical Industries Ltd.
• 16.7. Bayer AG
• 16.8. CLINUVEL PHARMACEUTICALS LTD
• 16.9. Strides Pharma Science Limited
• 16.10.Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer